Maze Therapeutics (MAZE) Gross Margin (2026)

Maze Therapeutics (MAZE) posted Gross Margin of 91.04% for Q1 2026.

Maze Therapeutics (MAZE) Gross Margin (2026) Analysis & Trends

Maze Therapeutics has reported Gross Margin for 1 years, with the latest figure at 91.04% in Q1 2026.

Peer Comparison

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Gross Margin (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn	85.33%
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn	91.59%
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn	90.68%
4	Revolution Medicines	43.64 Bn	43.64 Bn	-	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn	89.76%
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn	60,631,834.75%
7	Royalty Pharma	33.72 Bn	35.84 Bn	-	-
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn	76.90%
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn	84.20%
10	Maze Therapeutics	1.51 Bn	1.51 Bn	-	-

Historic Data

Download Data

Date	Value
Mar 31, 2026	91.04%